OncLive TV

Claire Harrison, MD, FRCP, FRCPath, discusses factors informing treatment selection for patients with myelofibrosis.

Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.

Hyun Woong Cho, MD, PhD, explains the rationale for assessing niraparib/bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Scott Tykodi, MD, PhD, discusses data from CheckMate 214 for nivolumab plus ipilimumab vs sunitinib in favorable-risk advanced RCC.

Paolo Tarantino, MD, the clinical impact of the KATHERINE trial in reshaping the post-surgical treatment algorithm for HER2+ breast cancer care.

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.

Douglas B. Flora, MD, LSSBB, discusses the potential utility of GPT models for improving clinical trial screening and workflows in oncology.

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R CLL.

I. Alex Bowman, MD, discusses recommended strategies for kidney cancer risk reduction.

Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.

Núria Agustí, MD, discusses patient eligibility in a cohort study assessing adjuvant chemoradiotherapy vs radiotherapy alone in patients with cervical cancer.

Virginia Kaklamani, MD, DSc, discusses inavolisib's efficacy in PIK3CA-mutated metastatic breast cancer, as well as the importance of biomarker testing.

Jeffrey Zonder, MD, discusses the need for increased screening for patients who are at higher risk of developing multiple myeloma.

Francisco J. Hernandez-Ilizaliturri, MD, discusses the rationale behind assessing immunologic changes seen with venetoclax treatment in patients with CLL.

Komal Jhaveri, MD, FACP, discusses the success of the INAVO120 trial of inavolisib/palbociclib/fulvestrant in PIK3CA-mutated metastatic breast cancer.

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

Marc R. Matrana, MD, shares his approach to navigating treatment selection when initiating therapy for patients with RCC.

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.

Jamile M. Shammo, MD, discusses future directions for investigating JAK inhibitor–based combination regimens in transfusion-dependent myelofibrosis.

Sara M. Tolaney, MD, MPH, discusses the ideal time for patients with HR-positive breast cancer to undergo genetic testing for ESR1 mutations.

Oleg Gluz, MD, discusses research assessing de-escalated chemotherapy and endocrine therapy combinations in HR-positive, HER2-positive early breast cancer.

Van Karlyle Morris, MD, discusses data supporting the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H unresectable or metastatic CRC.

Paul G. Richardson, MD, discusses 2 quadruplet regimens for the treatment of patients with newly diagnosed multiple myeloma and changes in administration.

R. Lor Randall, MD, FACS, discusses the benefits of a 3-dimensional model of the sarcoma tumor microenvironment for studying metastasis control mechanisms.

R. Lor Randall, MD, FACS, discusses the value of collaboration between oncologists and biomedical engineers to develop preclinical sarcoma models.

Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.

Paolo Tarantino, MD, discusses considerations around the frontline treatment of metastatic HER2-positive breast cancer.